Strategy

ORYZON genomics is a biopharmaceutical company based in Barcelona, and focused on the exploitation of biomarkers identified through genomics and proteomics in three fields: DIAGNOSTICS, PERSONALIZED MEDICINE and THERAPY.

In DIAGNOSTICS AND PERSONALIZED MEDICINE, our strategy is to market our products and services directly in Spain and the South of Europe through our ORYZONDX portal, which will be launched in Q4 2011. Our product pipeline contains products that were developed inside the company like GynEC®-DX or ColoBRAF™, and selected in-licensed products that fit in our business model like Cxbladder®.

ORYZON has been accredited and registered with the status of Clinical Genetic Laboratory by the General Directorate of Sanitary Resources of Catalonia.
At the international level, we look for global or regional partners that can commercialize our products in a fast and efficient manner.

In THERAPY, our business model is the development of NCEs and monoclonal antibodies directed against novel targets identified in our biomarker discovery programs in the fields of NEURODEGENERATION and CANCER.

Our pipeline is preclinical and we aim to reach the clinical phase in 2012.

We have generated a broad patent portfolio to protect our developments and are willing to consider out-licensing to experienced companies that can accelerate the preclinical and clinical development of our drugs for different indications.